|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Roberts LR, Sirlin CB, Zaiem F, Almasri J,
Prokop LJ, Heimbach JK, Murad MH and Mohammed K: Imaging for the
diagnosis of hepatocellular carcinoma: A systematic review and
meta-analysis. Hepatology. 67:401–421. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Torbenson MS: Morphologic subtypes of
hepatocellular carcinoma. Gastroenterol Clin North Am. 46:365–391.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Watanabe Y, Matsumoto N, Ogawa M, Moriyama
M and Sugitani M: Sarcomatoid hepatocellular carcinoma with
spontaneous intraperitoneal bleeding. Intern Med. 54:1613–1617.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lv TR, Hu HJ, Regmi P, Liu F and Li FY:
Sarcomatoid hepatocellular carcinoma versus conventional
hepatocellular carcinoma: A systematic review and meta-analysis. J
Cancer Res Clin Oncol. 148:1685–1696. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Benusiglio PR, Couve S, Gilbert-Dussardier
B, Deveaux S, Le Jeune H, Da Costa M, Fromont G, Memeteau F, Yacoub
M, Coupier I, et al: A germline mutation in PBRM1 predisposes to
renal cell carcinoma. J Med Genet. 52:426–430. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hwang S, Lee SG, Lee YJ, Ahn CS, Kim KH,
Park KM, Moon KM, Moon DB, Ha TY, Yu ES and Choi GW: Prognostic
impact of sarcomatous change of hepatocellular carcinoma in
patients undergoing liver resection and liver transplantation. J
Gastrointest Surg. 12:718–724. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liao SH, Su TH, Jeng YM, Liang PC, Chen
DS, Chen CH and Kao JH: Clinical manifestations and outcomes of
patients with sarcomatoid hepatocellular carcinoma. Hepatology.
69:209–221. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kojiro M, Sugihara S, Kakizoe S, Nakashima
O and Kiyomatsu K: Hepatocellular carcinoma with sarcomatous
change: A special reference to the relationship with anticancer
therapy. Cancer Chemother Pharmacol. 23 (Suppl):S4–S8. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lu J, Xiong XZ, Li FY, Ye H, Lin YX, Zhou
RX, Cai YL, Jin YW and Cheng NS: Prognostic significance of
sarcomatous change in patients with hepatocellular carcinoma after
surgical resection. Ann Surg Oncol. 22 (Suppl 3):S1048–S1056. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Calderaro J, Couchy G, Imbeaud S, Amaddeo
G, Letouzé E, Blanc JF, Laurent C, Hajji Y, Azoulay D, Bioulac-Sage
P, et al: Histological subtypes of hepatocellular carcinoma are
related to gene mutations and molecular tumour classification. J
Hepatol. 67:727–738. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Morisue R, Kojima M, Suzuki T, Nakatsura
T, Ojima H, Watanabe R, Sugimoto M, Kobayashi S, Takahashi S,
Konishi M, et al: Sarcomatoid hepatocellular carcinoma is distinct
from ordinary hepatocellular carcinoma: Clinicopathologic,
transcriptomic and immunologic analyses. Int J Cancer. 149:546–560.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang C, Feng S, Tu Z, Sun J, Rui T, Zhang
X, Huang H, Ling Q and Zheng S: Sarcomatoid hepatocellular
carcinoma: From clinical features to cancer genome. Cancer Med.
10:6227–6238. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ministry of Education Culture, Sports,
Science and Technology, Ministry of Health, Labour and Welfare, and
Ministry of Economy, Trade and Industry, . Ethical Guidelines for
Medical and Biological Research Involving Human Subjects.
https://www.mhlw.go.jp/content/001077424.pdfJanuary
19–2024(In Japanese).
|
|
15
|
Zhou Y, Zhou B, Pache L, Chang M,
Khodabakhshi AH, Tanaseichuk O, Benner C and Chanda SK: Metascape
provides a biologist-oriented resource for the analysis of
systems-level datasets. Nat Commun. 10:15232019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
De Velasco MA, Kura Y, Ando N, Sako N,
Banno E, Fujita K, Nozawa M, Yoshimura K, Sakai K, Yoshikawa K, et
al: Context-Specific efficacy of apalutamide therapy in preclinical
models of pten-deficient prostate cancer. Cancers (Basel).
13:39752021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pena-Llopis S, Vega-Rubin-de-Celis S, Liao
A, Leng N, Pavía-Jiménez A, Wang S, Yamasaki T, Zhrebker L,
Sivanand S, Spence P, et al: BAP1 loss defines a new class of renal
cell carcinoma. Nat Genet. 44:751–759. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bankhead P, Loughrey MB, Fernandez JA,
Dombrowski Y, McArt DG, Dunne PD, McQuaid S, Gray RT, Murray LJ,
Coleman HG, et al: QuPath: Open source software for digital
pathology image analysis. Sci Rep. 7:168782017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Eckel-Passow JE, Serie DJ, Cheville JC, Ho
TH, Kapur P, Brugarolas J, Thompson RH, Leibovich BC, Kwon ED,
Joseph RW and Parker AS: BAP1 and PBRM1 in metastatic clear cell
renal cell carcinoma: Tumor heterogeneity and concordance with
paired primary tumor. BMC Urol. 17:192017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Carril-Ajuria L, Santos M, Roldan-Romero
JM, Rodriguez-Antona C and de Velasco G: Prognostic and predictive
value of PBRM1 in clear cell renal cell carcinoma. Cancers (Basel).
12:162019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Brugarolas J: PBRM1 and BAP1 as novel
targets for renal cell carcinoma. Cancer J. 19:324–332. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
da Costa WH, Rezende M, Carneiro FC, Rocha
RM, da Cunha IW, Carraro DM, Guimaraes GC and de Cassio Zequi S:
Polybromo-1 (PBRM1), a SWI/SNF complex subunit is a prognostic
marker in clear cell renal cell carcinoma. BJU Int. 113:E157–E163.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Porter EG and Dykhuizen EC: Individual
bromodomains of polybromo-1 contribute to chromatin association and
tumor suppression in clear cell renal carcinoma. J Biol Chem.
292:2601–2610. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Robert C, Thomas L, Bondarenko I, O'Day S,
Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, et al:
Ipilimumab plus dacarbazine for previously untreated metastatic
melanoma. N Engl J Med. 364:2517–2526. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pawlowski R, Muhl SM, Sulser T, Krek W,
Moch H and Schraml P: Loss of PBRM1 expression is associated with
renal cell carcinoma progression. Int J Cancer. 132:E11–E17. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Burrows AE, Smogorzewska A and Elledge SJ:
Polybromo-associated BRG1-associated factor components BRD7 and
BAF180 are critical regulators of p53 required for induction of
replicative senescence. Proc Natl Acad Sci USA. 107:14280–14285.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Macher-Goeppinger S, Keith M, Tagscherer
KE, Singer S, Winkler J, Hofmann TG, Pahernik S, Duensing S,
Hohenfellner M, Kopitz J, et al: PBRM1 (BAF180) protein is
functionally regulated by p53-induced protein degradation in renal
cell carcinomas. J Pathol. 237:460–471. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xia W, Nagase S, Montia AG, Kalachikov SM,
Keniry M, Su T, Memeo L, Hibshoosh H and Parsons R: BAF180 is a
critical regulator of p21 induction and a tumor suppressor mutated
in breast cancer. Cancer Res. 68:1667–1674. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu T, Xia Q, Zhang H, Wang Z, Yang W, Gu
X, Hou T, Chen Y, Pei X, Zhu G, et al: CCL5-dependent mast cell
infiltration into the tumor microenvironment in clear cell renal
cell carcinoma patients. Aging (Albany NY). 12:21809–21836. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Guo C, Yang G, Khun K, Kong X, Levy D, Lee
P and Melamed J: Activation of Stat3 in renal tumors. Am J Transl
Res. 1:283–290. 2009.PubMed/NCBI
|
|
31
|
Horiguchi A, Oya M, Shimada T, Uchida A,
Marumo K and Murai M: Activation of signal transducer and activator
of transcription 3 in renal cell carcinoma: A study of incidence
and its association with pathological features and clinical
outcome. J Urol. 168:762–765. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hsu CS, Chao YC, Lin HH, Chen DS and Kao
JH: Systematic Review: Impact of interferon-based therapy on
HCV-related hepatocellular carcinoma. Sci Rep. 5:99542015.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Miao D, Margolis CA, Gao W, Voss MH, Li W,
Martini DJ, Norton C, Bossé D, Wankowicz SM, Cullen D, et al:
Genomic correlates of response to immune checkpoint therapies in
clear cell renal cell carcinoma. Science. 359:801–806. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
da Costa WH, da Cunha IW, Fares AF,
Bezerra SM, Shultz L, Clavijo DA, da Silva DV, Netto GJ, Guimaraes
GC and Cassio Zequi S: Prognostic impact of concomitant loss of
PBRM1 and BAP1 protein expression in early stages of clear cell
renal cell carcinoma. Urol Oncol. 36:243 e1–243 e8. 2018.
View Article : Google Scholar : PubMed/NCBI
|
